Get the Stockscreener App
5.935
1.07%
-0.145
Larimar Therapeutics Inc stock is traded at $5.935, with a volume of 197.34K.
It is down -1.07% in the last 24 hours and down -20.12% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$6.08
Open:
$6.12
24h Volume:
197.34K
Relative Volume:
0.30
Market Cap:
$387.94M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-6.4511
EPS:
-0.92
Net Cash Flow:
$-33.46M
1W Performance:
-20.54%
1M Performance:
-20.12%
6M Performance:
-23.76%
1Y Performance:
+95.29%
1-Day Range:
$5.68
$6.12
1-Week Range:
$5.68
$7.615
52-Week Range:
$3.09
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LRMR | 5.99 | 387.94M | 0 | -36.95M | -33.46M | -0.92 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.50 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times
Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire
Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat
(LRMR) Trading Signals - Stock Traders Daily
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com
Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com
When (LRMR) Moves Investors should Listen - Stock Traders Daily
What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Larimar Therapeutics Q3 2024 Financial Update - TipRanks
Larimar: Q3 Earnings Snapshot - CTPost
Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpHere's Why - MarketBeat
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
(LRMR) Investment Analysis and Advice - Stock Traders Daily
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance
Larimar initiated with bullish view at Oppenheimer on lead drug - MSN
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha
Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat
(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily
Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle
Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St
Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News
Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex
Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha
How To Trade (LRMR) - Stock Traders Daily
Larimar Therapeutics Inc [LRMR] Shares Rise 3.66 % on Thursday - Knox Daily
Quarry LP Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flynn James E | Director |
Feb 16 '24 |
Buy |
8.74 |
4,290,617 |
37,499,993 |
6,151,406 |
| THOMAS FRANK E | Director |
Feb 14 '24 |
Buy |
11.00 |
2,000 |
22,000 |
2,000 |
| Shankar Gopi | Chief Development Officer |
Dec 07 '23 |
Buy |
3.73 |
5,000 |
18,662 |
5,000 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):